Why dual-pathway targeting is more effective Single pathway limitations: GLP-1 alone eventually plateaus Body compensates over time Weight loss slows after 6-12 months Some people don't respond optimally Dual pathway advantages: Harder for body to compensate Multiple redundant systems targeted Sustained weight loss longer Better for non-responders to single therapy Mechanistic synergy: Amylin + GLP-1 naturally work together Both released after meals normally Physiologic combination Not forcing unnatural state Clinical implications: Patients who plateau on semaglutide benefit from adding cagrilintide Initial combination produces maximum results May prevent or delay weight regain Better long-term outcomes Cagrilintide and semaglutide dosing protocols Proper dosing ensures maximum efficacy with manageable side effects
Once they appear, they tend to stay unless removed with treatments like laser, chemical peels, or pigment-targeting creams
Why they work together: Stimulates Type I, III, and IV collagen Enhances retinol's anti-aging effects Minimal irritation risk Supports skin barrier function Application strategy: Layer together in same routine (peptide first) OR separate AM/PM Signal peptides vs neurotransmitter peptides with retinol Signal peptides (like Matrixyl, Syn-Coll): Best compatibility with retinol Work synergistically Can apply together or separately Neurotransmitter peptides (like Argireline, Leuphasyl): Good compatibility but better separated Different pH requirements may interfere Apply separately (AM vs PM) for best results Peptides to avoid combining with retinol AHA/BHA peptide combinations: Products that combine peptides with acids (glycolic, salicylic) Adding retinol on top = potential over-exfoliation Use peptide+acid products separately from retinol nights High-dose vitamin C + peptides + retinol: All three together may be too much for sensitive skin Vitamin C (L-ascorbic acid) can destabilize retinol Better to separate: Vitamin C AM, Peptides + Retinol PM See our glow peptides guide for complete skincare peptide protocols
Ufnal M, Zadlo A, et al
A 2025 preliminary safety study administered intravenous BPC-157 to 2 participants at escalating doses with no adverse effects reported, but the extremely limited sample size prevents meaningful conclusions
Verifying age through government ID, facial analysis, or trusted data sources helps catch both issues early
